Published in Proc Natl Acad Sci U S A on April 01, 1980
Cyclic nucleotides in procaryotes. Microbiol Rev (1981) 2.67
Agrobacterium Ti plasmid indoleacetic acid gene is required for crown gall oncogenesis. Proc Natl Acad Sci U S A (1982) 1.75
Regulation of fatty acid degradation in Escherichia coli: analysis by operon fusion. J Bacteriol (1981) 1.69
Mechanism for transcriptional action of cyclic AMP in Escherichia coli: entry into DNA to disrupt DNA secondary structure. Proc Natl Acad Sci U S A (1981) 1.13
Effects of indole-3-acetic acid on the transcriptional activities and stress tolerance of Bradyrhizobium japonicum. PLoS One (2013) 0.81
First approximation of a stereochemical rationale for the genetic code based on the topography and physicochemical properties of "cavities" constructed from models of DNA. Proc Natl Acad Sci U S A (1981) 0.76
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res (1975) 17.12
Cyclic AMP receptor protein of E. coli: its role in the synthesis of inducible enzymes. Proc Natl Acad Sci U S A (1970) 13.26
ADENOSINE 3',5'-PHOSPHATE IN ESCHERICHIA COLI. J Biol Chem (1965) 11.04
Pleiotropic deficiency of carbohydrate utilization in an adenyl cyclase deficient mutant of Escherichia coli. Biochem Biophys Res Commun (1969) 9.20
Determination of the order of mutational sites governing L-arabinose utilization in Escherichia coli B/r bv transduction with phage Plbt. Virology (1959) 7.97
Regulation of beta-galactosidase synthesis in Escherichia coli by cyclic adenosine 3',5'-monophosphate. J Biol Chem (1968) 7.54
Cyclic adenosine monophosphate in bacteria. Science (1970) 7.53
Studies on 3-Indoleacetic Acid Metabolism. II. Some Products of the Metabolism of Exogenous Indoleacetic Acid in Plant Tissues. Plant Physiol (1956) 7.40
Positive control of enzyme synthesis by gene C in the L-arabinose system. J Bacteriol (1965) 6.59
Genetic characterization of mutations which affect catabolite-sensitive operons in Escherichia coli, including deletions of the gene for adenyl cyclase. J Bacteriol (1973) 4.03
Adenyl cylase. I. Distribution, preparation, and properties. J Biol Chem (1962) 3.69
Adenosine 3':5'-cyclic monophosphate as mediator of catabolite repression in Escherichia coli. Proc Natl Acad Sci U S A (1975) 3.60
The role of the lac promotor locus in the regulation of beta-galactosidase synthesis by cyclic 3',5'-adenosine monophosphate. Proc Natl Acad Sci U S A (1968) 2.92
DNA sequence of the araBAD promoter in Escherichia coli B/r. Proc Natl Acad Sci U S A (1978) 2.51
Cyclic guanosine 3':5'-monophosphate in Escherichia coli and Bacillus lichenformis. J Biol Chem (1974) 2.37
Effect of iproniazid on serotonin metabolism in vivo. J Pharmacol Exp Ther (1957) 2.16
L-arabinose binding protein from Escherichia coli B-r. J Bacteriol (1969) 1.75
Increase in tissue serotonin following administration of its precursor 5-hydroxytryptophan. J Biol Chem (1957) 1.74
Biochemical findings relating to the action of serotonin. Ann N Y Acad Sci (1957) 1.61
Potent diphtheria toxin within the cells of C. diphtheriae. Nature (1954) 1.58
Mutations affecting catabolite repression of the L-arabinose regulon in Escherichia coli B/r. J Bacteriol (1976) 1.55
A role for a pyridoxne derivative in the multivalent repression of the isoleucine and valine biosynthetic enzymes. Biochem Biophys Res Commun (1973) 1.22
Metabolic interlock. The multi-metabolite control of prephenate dehydratase activity in Bacillus subtilis. J Biol Chem (1970) 1.12
Diverse directional changes of cGMP relative to cAMP in E. coli. Biochem Biophys Res Commun (1975) 1.11
New amino acid regulatory locus having unusual properties in heterozygous merodiploids. J Bacteriol (1972) 1.09
Enzymatic O-methylation of N-acetylserotonin to melatonin. Science (1960) 1.07
A new locus (leuK) affecting the regulation of branched-chain amino acid, histidine, and tryptophan biosynthetic enzymes. J Bacteriol (1978) 0.95
Imidazole acetic acid as a substitute for cAMP. Biochem Biophys Res Commun (1979) 0.87
Formation of adenosine-3,5-phosphate (cyclic adenylate) and its relation to the action of several neurohormones or hormones. Acta Endocrinol Suppl (Copenh) (1960) 0.85
Neurochemical differences between two strains of mice. Science (1962) 0.84
The influence of neuroamines on the oxidation of glucose by the anterior pituitary. I. The role of monoamine oxidase. J Biol Chem (1962) 0.84
Gene regulation: the involvement of stereochemical recognition in DNA-small molecule interactions. Perspect Biol Med (1977) 0.84
The hypoglycemic and insulinase-inhibitory action of some plant growth regulators. Endocrinology (1956) 0.82
Chirality and stereochemical recognition in DNA-phytohormone interactions: a model approach. Orig Life (1978) 0.81
Stereochemical recognition in nucleic acid-amino acid interactions and its implications in biological coding: a model approach. Perspect Biol Med (1979) 0.80
Effect of tryptophan analogs on derepression of the Escherichia coli tryptophan operon by indole-3-propionic acid. J Bacteriol (1978) 0.79
CENTRAL NERVOUS SYSTEM SEROTONIN AND NOREPINEPHRINE LOCALIZATION IN EMOTIONAL AND NON-EMOTIONAL STRAINS IN MICE. Nature (1964) 0.79
Neurochemical differences between two strains of mice. Nature (1963) 0.78
Tumours resulting from parthenogenesis induced by plant hormones in albino rats. Acta Endocrinol (Copenh) (1950) 0.77
"Biogenic" aldehyde metabolism relation to pentose shunt activity in brain. Biochem Pharmacol (1974) 0.77
Incorporation of radioactivity from labeled serotonin and tryptamine into acid-insoluble material from subcellular fractions of brain. I. The nature of the substrate. Biochemistry (1968) 0.77
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
The phosphatase Cdc14 triggers mitotic exit by reversal of Cdk-dependent phosphorylation. Mol Cell (1998) 6.20
Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill (2012) 4.96
Transcription, organization, and sequence of an auxin-regulated gene cluster in soybean. Plant Cell (1989) 4.79
Sec9 is a SNAP-25-like component of a yeast SNARE complex that may be the effector of Sec4 function in exocytosis. Cell (1994) 4.46
Efficacy and safety of lidocaine-prilocaine cream for pain during circumcision. N Engl J Med (1997) 4.37
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol (1994) 3.71
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet (1988) 3.32
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
The antibody response in HIV-1 infection. AIDS (1997) 2.79
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med (1999) 2.77
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol (2001) 2.66
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol (1998) 2.49
A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol (1997) 2.46
Regulation of isoleucine-valine biosynthesis in an ilvDAC deletion strain of Escherichia coli K-12. Biochem Biophys Res Commun (1974) 2.35
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol (2001) 2.30
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A (1997) 2.20
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol (2001) 2.16
Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol (2000) 2.09
The McKee-Farrar total hip replacement. Preliminary results and complications of 368 operations performed in five general hospitals. J Bone Joint Surg Am (1972) 2.08
Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J Infect Dis (1999) 1.96
Phospholipid transfer proteins: a biological debut. Trends Cell Biol (1991) 1.83
Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine (1999) 1.83
Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acquir Immune Defic Syndr (1989) 1.75
Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol (1996) 1.71
Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis (1998) 1.71
Schistosomula of Schistosoma mansoni use lysophosphatidylcholine to lyse adherent human red blood cells and immobilize red cell membrane components. J Cell Biol (1986) 1.71
The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012. Euro Surveill (2012) 1.67
Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.64
Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A (1989) 1.64
Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother (1999) 1.63
Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol (1999) 1.62
Psychiatric applications of bromocriptine therapy. J Clin Psychiatry (1990) 1.61
Luteal phase defect: the sensitivity and specificity of diagnostic methods in common clinical use. Fertil Steril (1994) 1.58
Evaluation of a point-of-care blood test for identification of Ebola virus disease at Ebola holding units, Western Area, Sierra Leone, January to February 2015. Euro Surveill (2015) 1.56
Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol (1999) 1.55
Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: characterizing animals with low antibody responses and rapid progression. J Gen Virol (1998) 1.51
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A (2000) 1.50
A role for phosphatidylinositol transfer protein in secretory vesicle formation. Nature (1995) 1.50
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis (1998) 1.47
Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses (2006) 1.47
Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol (1997) 1.45
In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol (2001) 1.45
Role of leucyl-tRNA synthetase in regulation of branched-chain amino-acid transport. Proc Natl Acad Sci U S A (1975) 1.44
Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses (1998) 1.41
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol (1998) 1.39
Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J Virol (2004) 1.39
Cardiac troponin. See ya later, CK! Chest (1997) 1.38
Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol (1999) 1.37
Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. J Infect Dis (1995) 1.37
The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO. Neurology (2010) 1.36
CD4+-T-cell and CD20+-B-cell changes predict rapid disease progression after simian-human immunodeficiency virus infection in macaques. J Virol (1998) 1.36
Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc (1994) 1.36
Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci U S A (1992) 1.35
Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV. Immunol Lett (1999) 1.34
Genetic linkage relationships of seven DNA probes with Duchenne and Becker muscular dystrophy. Hum Genet (1985) 1.33
Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine (1993) 1.32
Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity. J Infect Dis (1995) 1.31
Phosphatidylinositol transfer proteins: the long and winding road to physiological function. Trends Cell Biol (1998) 1.29
Patterns of adaptive behavior in very young children with autism. Am J Ment Retard (1999) 1.28
The yeast and mammalian isoforms of phosphatidylinositol transfer protein can all restore phospholipase C-mediated inositol lipid signaling in cytosol-depleted RBL-2H3 and HL-60 cells. Proc Natl Acad Sci U S A (1996) 1.25
When groups are not created equal: effects of group status on the formation of intergroup attitudes in children. Child Dev (2001) 1.24
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol (2013) 1.23
A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera. Biochem Biophys Res Commun (1987) 1.20
Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1) pathogenesis. AIDS Res Hum Retroviruses (1987) 1.19
Lateral mobility of class I histocompatibility antigens in B lymphoblastoid cell membranes: modulation by cross-linking and effect of cell density. J Cell Biol (1987) 1.19
Infection of the HTLV-II-bearing T-cell line C3 with HTLV-III/LAV is highly permissive and lytic. Virology (1986) 1.18
Photomorphogenesis, photosynthesis, and seed yield of wheat plants grown under red light-emitting diodes (LEDs) with and without supplemental blue lighting. J Exp Bot (1997) 1.18
Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J Virol (1998) 1.18
Gene conversion-like mechanisms may generate polymorphism in human class I genes. EMBO J (1986) 1.17
Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology (2000) 1.14
Multivalent regulation of isoleucine-valine transaminase in an Escherichia coli K-12 ilvA deletion strain. J Bacteriol (1977) 1.14
Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology (1990) 1.14
Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1987) 1.13
Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol (2009) 1.13
Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol Lett (2001) 1.13
Prescription-writing with a PC. Comput Methods Programs Biomed (1986) 1.12
Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J Virol (1999) 1.11
Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology (1997) 1.11
Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol (1994) 1.10
Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses (2001) 1.09
Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. Lancet (1987) 1.09
New amino acid regulatory locus having unusual properties in heterozygous merodiploids. J Bacteriol (1972) 1.09
Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines? Lancet (1988) 1.07
Expression of the protein kinase C substrate pleckstrin in macrophages: association with phagosomal membranes. J Immunol (1999) 1.07